Improving OS in MCL
An observational study was undertaken by the Nordic Lymphoma Group to determine the efficacy of different first-line therapies in patients with mantle cell lymphoma (MCL).
Data were gathered from the Danish and Swedish Lymphoma Registries for the period of 2000 to 2011. Patients (n = 1,389) were diagnosed with MCL with the median age of diagnosis being 71 years. Among those who received systemic therapy, both rituximab (n = 766; HR = 0.66; p = 0.001) and autologous stem cell transplant (n = 273; HR = 0.55, p = 0.004) were associated with improved overall survival (OS). Patients (n = 43) with stage II-III who received radiotherapy with curative intent showed a three-year OS of 93%. For more information, click here.